Syndax (SNDX) news
Recent news
Syndax Pharmaceuticals, Inc.: UBS cuts target price to $33 from $37
AInvest Wire · Aug 21, 2026Syndax Pharmaceuticals, Inc.: BofA Global Research cuts price objective to $26 from $29
Bank of America Global Research has revised its price target for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), lowering it to $26 from $29, while maintaining a Buy rating on the stock. This adjustment reflects evolving expectations around the commercialization timeline for Syndax’s key drug…
AInvest Wire · Aug 5, 2026Sndx still sees FY R&D expenses about $400M, est. $265.9M
AInvest Wire · Aug 4, 2026Syndax Pharmaceuticals 2Q loss/share 55c, est. loss/share 47c
AInvest Wire · Aug 4, 2026Syndax Pharmaceuticals - issues $250 mln of 2.25% convertible senior notes due 2031 - SEC filing
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) has issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 as part of a private placement. The transaction, which closed on June 10, 2026, is expected to generate net proceeds of approximately $243 million after…
AInvest Wire · Jun 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.